Patents by Inventor Eduard A. SERGIENKO

Eduard A. SERGIENKO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11806337
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: July 27, 2022
    Date of Patent: November 7, 2023
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
  • Publication number: 20230121698
    Abstract: Provided herein are small molecule modulators of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 20, 2023
    Inventors: Anthony PINKERTON, Eduard SERGIENKO, Yohei KIYOTSUKA, Katsuji KAGECHIKA, Yasunobu KUROSAKI, Yoshikazu ARAI, Masatoshi NAGAMOCHI, Koutaro ISHIBASHI
  • Publication number: 20230116770
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: July 27, 2022
    Publication date: April 13, 2023
    Inventors: Stephen GARDELL, Anthony B. PINKERTON, Eduard SERGIENKO, Hampton SESSIONS
  • Patent number: 11452717
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: September 27, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Stephen Gardell, Anthony B. Pinkerton, Eduard Sergienko, Hampton Sessions
  • Publication number: 20210161873
    Abstract: Provided herein are small molecule activators of Nicotinamide Phosphoribosyltransferase (NAMPT), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: January 9, 2018
    Publication date: June 3, 2021
    Inventors: Stephen GARDELL, Anthony B. PINKERTON, Eduard SERGIENKO, Hampton SESSIONS
  • Patent number: 10196369
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: February 5, 2019
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Patent number: 9776979
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Grant
    Filed: September 26, 2014
    Date of Patent: October 3, 2017
    Assignee: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE
    Inventors: Anthony B. Pinkerton, Robert Ardecky, Eduard A. Sergienko, Marcos Gonzalez-Lopez, Santhi Reddy Ganji, Jiwen Zou
  • Publication number: 20160214951
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. EBI2 is a therapeutic target for the treatment of a variety of diseases or conditions. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Application
    Filed: September 26, 2014
    Publication date: July 28, 2016
    Inventors: Anthony B. PINKERTON, Robert ARDECKY, Eduard A. SERGIENKO, Marcos GONZALEZ-LOPEZ, Santhi Reddy GANJI, Jiwen ZOU
  • Publication number: 20160176875
    Abstract: Provided herein are small molecule Epstein-Barr virus-induced G-protein coupled receptor 2 (EBI2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, EBI2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease.
    Type: Application
    Filed: September 26, 2014
    Publication date: June 23, 2016
    Inventors: Anthony B. PINKERTON, Robert ARDECKY, Eduard A. SERGIENKO, Marcos GONZALEZ-LOPEZ, Santhi Reddy GANJI, Jiwen ZOU
  • Patent number: 8686003
    Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: April 1, 2014
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Jose Luis Millan, Eduard Sergienko
  • Publication number: 20120095032
    Abstract: The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
    Type: Application
    Filed: December 6, 2011
    Publication date: April 19, 2012
    Inventors: Tomas Mustelin, Lutz Tautz, Nicolas David Peter Cosford, Eduard Sergienko
  • Publication number: 20120095044
    Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.
    Type: Application
    Filed: December 7, 2011
    Publication date: April 19, 2012
    Inventors: Jose Luis Millan, Eduard Sergienko
  • Patent number: 8119693
    Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.
    Type: Grant
    Filed: May 8, 2008
    Date of Patent: February 21, 2012
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Jose Luis Millan, Eduard Sergienko
  • Publication number: 20100016313
    Abstract: Disclosed are modulators, i.e., activators and inhibitors, of Intestinal Alkaline Phosphatase (IAP). Also disclosed are methods for treating bacterial infections of the intestinal tract and methods for maintaining the health of the intestinal tract using IAP activators. Further disclosed are methods to assist in weight gain of emaciated patients and those having reduced or negligible fat absorption using IAP inhibitors.
    Type: Application
    Filed: May 19, 2009
    Publication date: January 21, 2010
    Applicant: Burnham Institute for Medical Research
    Inventors: Jose Luis Millan, Sonoko Narisawa, Eduard Sergienko
  • Publication number: 20090156560
    Abstract: Disclosed herein are compounds that are tissue-nonspecific alkaline phosphatase inhibitors. The disclosed compounds are used to treat, prevent, or abate vascular calcification, arterial calcification and other cardiovascular diseases.
    Type: Application
    Filed: May 8, 2008
    Publication date: June 18, 2009
    Inventors: JOSE LUIS MILLAN, EDUARD SERGIENKO
  • Publication number: 20090118135
    Abstract: An assay for determining compounds that inhibit activity of a BCl-2 protein, or affect conversion of Bcl-2 from an antiapoptotic to a proapoptotic form are described. In addition, compounds that modulate the function of anti-apoptotic proteins such as Bcl-2 and related Bcl-2 family members are identified.
    Type: Application
    Filed: June 2, 2008
    Publication date: May 7, 2009
    Applicant: The Burnham Institute
    Inventors: John C. Reed, Kenneth Yip, Eduard Sergienko, Ying Su
  • Publication number: 20090105240
    Abstract: The present disclosure relates to methods for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure further relates to compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome and acute myelogenous leukemia. The present disclosure also relates to methods for identifying compounds that can be used for treating leukemia, pre-leukemic conditions, as well as myelodysplastic syndrome.
    Type: Application
    Filed: October 17, 2007
    Publication date: April 23, 2009
    Inventors: Tomas Mustelin, Lutz Tautz, Nicholas David Peter Cosford, Eduard Sergienko
  • Publication number: 20090069324
    Abstract: Compounds that bind to Bfl-1 as well as conjugates of such compounds are provided. Various embodiments additionally provide methods of using such compounds to identify additional anti-apoptotic Bfl-1 binding compounds. Methods of using such compounds to increase apoptosis in a cell are also provided.
    Type: Application
    Filed: May 30, 2008
    Publication date: March 12, 2009
    Applicant: The Burnham Institute
    Inventors: John C. Reed, Dayong Zhai, Shinichi Kitada, Eduard Sergienko
  • Publication number: 20090053192
    Abstract: Disclosed herein are tissue-nonspecific alkaline phosphatase (TNAP) activators and uses thereof for promoting bone mineral deposition.
    Type: Application
    Filed: August 9, 2008
    Publication date: February 26, 2009
    Applicant: BURNHAM INSTITUTE FOR MEDICAL RESEARCH
    Inventors: Jose Luis Millan, Eduard Sergienko
  • Publication number: 20050208613
    Abstract: The present invention provides compositions containing a common ligand linked to a detectable moiety and provides methods for the preparation of such compositions. The present invention also provides methods for screening candidate ligands for binding to a NAD binding receptor, which include contacting a receptor with a candidate ligand and a composition of the invention followed by evaluation of receptor binding. The screening method of the present invention has broad applicability and can be used to screen large numbers of a wide variety of ligands. The present invention further provides methods for detecting the binding activity of a putative receptor, which include combining the putative receptor with a composition of the invention and evaluating the level of detectable moiety. The invention also provides kits useful for detection of receptors having NAD binding activity and for screening of candidate ligands that bind to a NAD binding receptor.
    Type: Application
    Filed: April 29, 2005
    Publication date: September 22, 2005
    Inventors: Yong Qin, Lin Yu, Mark Hansen, Eduard Sergienko, Bonnie Bertolaet, Daniel Sem